Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Recruiting now · Phase 4

Conditions studied: Diabetes Mellitus, Type 2 DM

In brief

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Key facts

Study ID

NCT06862739

Run by

Nabiqasim Industries (Pvt) Ltd

People needed

800

Starts

2025-10-30

Expected to finish

2026-06-30

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients of any gender
• Patients aged between 18-80 years
• Patients having HbA1c 8 % or above
• Patients diagnosed with type II diabetes (more than at least 06 months)
• Patients already on at least 02 or more anti-diabetic agents
• Patients not allergic to empagliflozin, linagliptin, or metformin

You may not qualify if…

• Patients with age less than 18
• Patients with Type-I diabetes
• Patients having diabetes for less than 06 months
• Patients on GLP-1 and GIP
• Patients who are pregnant or lactating females
• Patients with decompensated chronic liver disease (DCLD)
• Patients with eGFR less than 30 ml
• Patients with end-stage heart failure (NYHA Class 4)
• Patients who are allergic to empagliflozin, linagliptin, or metformin
• Patients who are not willing to consent
• Patients who are unable to give medical history

Where it is running

• Faisalabad clinics — Faisalabad, Punjab Province, Pakistan (enrolling)
• Aap ka Clinic — Lahore, Punjab Province, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.